The newest player in US pharmaceuticals? Samsung. The electronics giant is teaming up with Merck to release an alternative to Johnson & Johnson’s rheumatoid arthritis drug, Remicade, which will be roughly 35% cheaper than the drug’s list price — currently more than $1,100 per vial, and $30,000 per year before discounts. “It is the Samsung business empire’s debut treatment in the world’s biggest drug market and reflects its desires to diversify beyond electronics,” explains The Wall Street Journal. Johnson & Johnson is trying to block the effort, saying Samsung’s new drug violates three of its patents. #SamsungPharmaceutical